Indaptus Therapeutics enters $20M equity purchase agreement with Lincoln Park Capital

Indaptus Therapeutics, Inc.

Lincoln Park committed to buy up to $20M of Indaptus common stock over 36 months (extendable to 48).
Company controls timing of sales; Lincoln Park cannot require purchases or engage in short selling.
Indaptus issued 142,450 initial commitment shares; up to 76,220 additional shares may follow after $10M sold.
Net proceeds will be used for working capital and general corporate purposes.
Agreement includes standard representations, indemnification, and automatic termination on bankruptcy.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Indaptus Therapeutics, Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at Up to $20,000,000 (effective 2022-12-22).

Action: entry
Agreement: equity purchase
Counterparty: Lincoln Park Capital Fund, LLC
Value: Up to $20,000,000
Effective: 2022-12-22

Exact text from the filing

On December, 22, 2022, Indaptus Therapeutics, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) and a registration rights agreement (the “Registration Rights Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park has committed to purchase up to $20.0 million of the Company’s common stock, $0.01 par value per share.

View on SEC.gov

Browse all material agreements →

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-036486

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.